| 品牌 | 货号 | 产品规格 | 价格(RMB) | 库存（上海） | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
| 源叶(MedMol) | S80962-5mg | ≥99% | ￥500.00元 | >10 | - | - | - |
|
| 源叶(MedMol) | S80962-10mg | ≥99% | ￥800.00元 | >10 | - | - | - |
|
| 源叶(MedMol) | S80962-25mg | ≥99% | ￥1750.00元 | >10 | - | - | - |
|
| 源叶(MedMol) | S80962-50mg | ≥99% | ￥2800.00元 | >10 | - | - | - |
|
Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
|
产品描述： Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||||||||||||||||||||
| 靶点： IL-6;IL-1;STAT3;Lipoxygenase;STAT;Interleukin | ||||||||||||||||||||
|
体内研究： At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug |
||||||||||||||||||||
|
参考文献： 1. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. 2. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
||||||||||||||||||||
| 溶解性： Soluble in DMSO、1M NaOH | ||||||||||||||||||||
| 保存条件： 2-8℃ | ||||||||||||||||||||
配置溶液浓度参考：
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
|---|
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京